Ieq Capital LLC Buys 14,780 Shares of Solventum Co. (NYSE:SOLV)

Ieq Capital LLC lifted its position in Solventum Co. (NYSE:SOLV) by 301.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,675 shares of the company’s stock after purchasing an additional 14,780 shares during the quarter. Ieq Capital LLC’s holdings in Solventum were worth $1,300,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Private Advisor Group LLC increased its position in Solventum by 73.9% in the fourth quarter. Private Advisor Group LLC now owns 34,684 shares of the company’s stock worth $2,291,000 after purchasing an additional 14,740 shares during the last quarter. SilverOak Wealth Management LLC increased its holdings in shares of Solventum by 5.2% in the 4th quarter. SilverOak Wealth Management LLC now owns 22,559 shares of the company’s stock worth $1,490,000 after buying an additional 1,118 shares during the last quarter. Venturi Wealth Management LLC raised its position in shares of Solventum by 2,284.6% during the 4th quarter. Venturi Wealth Management LLC now owns 1,240 shares of the company’s stock valued at $82,000 after buying an additional 1,188 shares in the last quarter. CIBC Asset Management Inc raised its position in shares of Solventum by 2.0% during the 4th quarter. CIBC Asset Management Inc now owns 19,673 shares of the company’s stock valued at $1,300,000 after buying an additional 382 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Solventum by 1.0% in the 4th quarter. Principal Financial Group Inc. now owns 171,376 shares of the company’s stock valued at $11,321,000 after acquiring an additional 1,761 shares during the last quarter.

Analysts Set New Price Targets

SOLV has been the topic of several analyst reports. Mizuho began coverage on Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective on the stock. Morgan Stanley increased their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, Piper Sandler lifted their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $68.29.

Solventum Price Performance

Shares of SOLV stock opened at $76.30 on Tuesday. The stock has a 50 day moving average price of $71.28 and a 200 day moving average price of $69.37. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.